Literature DB >> 3819604

The conflict between randomized clinical trials and the therapeutic obligation.

F Gifford.   

Abstract

The central dilemma concerning randomized clinical trials (RCTs) arises out of some simple facts about causal methodology (RCTs are the best way to generate the reliable causal knowledge necessary for optimally-informed action) and a prima facie plausible principle concerning how physicians should treat their patients (always do what it is most reasonable to believe will be best for the patient). A number of arguments related to this in the literature are considered. Attempts to avoid the dilemma fail. Appeals to informed consent and mechanisms for minimizing the resulting harm are important for policy, but informed consent is problematic and mechanisms for minimization of harm do not address the dilemma. Appeals to some sort of contract model of justification are promising and illuminating.

Entities:  

Keywords:  Analytical Approach; Biomedical and Behavioral Research; Philosophical Approach

Mesh:

Year:  1986        PMID: 3819604     DOI: 10.1093/jmp/11.4.347

Source DB:  PubMed          Journal:  J Med Philos        ISSN: 0360-5310


  4 in total

1.  Does diabetes prevention pay for itself? Evaluation of the M.O.B.I.L.I.S. program for obese persons.

Authors:  Jan Häußler; Friedrich Breyer
Journal:  Eur J Health Econ       Date:  2015-03-31

2.  An analysis of finder's fees in clinical research.

Authors:  E A Maher
Journal:  CMAJ       Date:  1994-01-15       Impact factor: 8.262

Review 3.  OARSI Clinical Trials Recommendations: Design and conduct of clinical trials of surgical interventions for osteoarthritis.

Authors:  J N Katz; E Losina; L S Lohmander
Journal:  Osteoarthritis Cartilage       Date:  2015-05       Impact factor: 6.576

4.  Efficient wavelength conversion of exchange magnons below 100 nm by magnetic coplanar waveguides.

Authors:  Ping Che; Korbinian Baumgaertl; Anna Kúkol'ová; Carsten Dubs; Dirk Grundler
Journal:  Nat Commun       Date:  2020-03-19       Impact factor: 14.919

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.